SAB BIOTHERAPEUTICS INC (SABS) Stock News
NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD
SABS Latest News, Press Relases and Analysis
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel...
SAB BIO to Participate in Upcoming Investor Conferences
Why Is SAB BIO Stock Trading Lower On Tuesday?
SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024
SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.
SAB BIO Appoints Lucy To as Chief Financial Officer
SAB BIO Appoints Lucy To as Chief Financial Officer ...
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
SABS stock results show that SAB Biotherapeutics missed analyst estimates for earnings per share the first quarter of 2024.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142...
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
SAB to host webinar event to discuss Phase 1 clinical trial topline results ...
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update...
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel...
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel...
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08,...
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company...
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
SAb Biotherapeutics Rebrands as SAB BIO
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1...
SAb Biotherapeutics Rebrands as SAB BIO
SAB BIO Appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a...
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
SAB Biotherapeutics Announces Departure of Chief Financial Officer
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a...
SAB Biotherapeutics Announces Departure of Chief Financial Officer
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics...
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
SAB Biotherapeutics Announces Q1 2024 Financial Results...